# Oral COVID Therapeutic - Update! | Sen-Jam Pharmaceutical

- Canonical URL: https://wefunder.com/feed/156804
- Entity ID: wefunder:feed_item:156804
- Published at: 2022-07-15 19:23:28 UTC
- Updated at: 2025-07-09 03:22:12 UTC

## Author
Jim Iversen

## Subject
Sen-Jam Pharmaceutical

## Content
We just returned from KVK Tech where we reviewed the Formulation progress of our Oral COVID therapeutic, SJP-002C.Everything is progressing as planned and we expect to be making our FDA submission in 6-9 months. Our phase 2 clinical trial is progressing and we are starting discussions with licensing partners around the world.Our oral COVID therapeutic has the potential to be a market disruptor of Pfizer's Paxlovid (Projected 2022 revenue of $22B) with the following points of differentiation:CostSafetyDrug:Drug Interaction ProfileBroader Spectrum for future variants/mutationsEase of distributionWe expect our efforts to be rewarded with 10-30% of the future oral COVID therapeutic market. At our suggested price point this could result in $335M to $1B in annual revenue.Our current Wefunder convertible note campaign ends on July 31st! The best time is invest is now for we will be starting another campaign at a much higher valuation.Thank you for your continued support!Jim